Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson's Disease

被引：0
|
作者：
Padoani, G.
Novello, S.
Pisano, C.
Caccia, C.
Melloni, E.
Vailati, S.
Keywood, C.
Morari, M.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
182
引用
收藏
页码：S81 / S82
页数：2
相关论文
共 50 条
  • [41] Real life evaluation of safinamide effectiveness in Parkinson's disease
    Mancini, Francesca
    Di Fonzo, Alessio
    Lazzeri, Giulia
    Borellini, Linda
    Silani, Vincenzo
    Lacerenza, Marco
    Comi, Cristoforo
    NEUROLOGICAL SCIENCES, 2018, 39 (04) : 733 - 739
  • [42] Safinamide in the treatment of URINARY symptoms in PARKinson's disease (SURINPARK)
    Gomez Lopez, A.
    Parees Moreno, I.
    Fanjul Arbos, S.
    Lopez Sendon, J. L.
    Martinez Castrillo, J. C.
    Alonso Canovas, A.
    MOVEMENT DISORDERS, 2019, 34 : S250 - S250
  • [43] Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson's disease patients
    Hofmann, W. E.
    MOVEMENT DISORDERS, 2020, 35 : S453 - S453
  • [44] The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
    Abbruzzese, Giovanni
    Barone, Paolo
    Lopiano, Leonardo
    Stocchi, Fabrizio
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2507 - 2517
  • [45] Safinamide monotherapy in early Parkinson's disease: A pilot study
    Gonzalez Hernandez, A.
    Fabre Pi, O.
    Miranda Bacallado, Y.
    Alemany Rodriguez, M. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 640 - 640
  • [46] Real life evaluation of safinamide effectiveness in Parkinson’s disease
    Francesca Mancini
    Alessio Di Fonzo
    Giulia Lazzeri
    Linda Borellini
    Vincenzo Silani
    Marco Lacerenza
    Cristoforo Comi
    Neurological Sciences, 2018, 39 : 733 - 739
  • [47] Spanish expert consensus on the use of safinamide in Parkinson's disease
    Valldeoriola, F.
    Grandas, F.
    Arbelo, J. M.
    Blazquez Estrada, M.
    Calopa Garriga, M.
    Campos-Arillo, V. M.
    Garcia Ruiz, P. J.
    Gomez Esteban, J. C.
    Leiva Santana, C.
    Martinez Castrillo, J. C.
    Mir, P.
    Salvador Aliaga, A.
    Vivancos Matellano, F.
    Yanez Bana, R. M.
    NEUROLOGIA, 2021, 36 (09): : 666 - 672
  • [48] The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease
    Perez-Lloret, Santiago
    Rascol, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (03) : 245 - 258
  • [49] Cerebral glutamate metabolism in Parkinson's disease:: an in vivo dynamic 13C NMS study in the rat
    Chassain, C
    Bielicki, G
    Donnat, JP
    Renou, JP
    Eschalier, A
    Durif, F
    EXPERIMENTAL NEUROLOGY, 2005, 191 (02) : 276 - 284
  • [50] Neuroprotection by safinamide in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease
    Sadeghian, M.
    Roach, A.
    Smith, K. J.
    MOVEMENT DISORDERS, 2011, 26 : S286 - S286
12345